Ascendis Pharma A/S (ASND) Set to Announce Earnings on Thursday

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) is scheduled to be announcing its earnings data after the market closes on Thursday, November 14th. Analysts expect the company to announce earnings of ($1.54) per share for the quarter.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its quarterly earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The business had revenue of $38.75 million for the quarter, compared to the consensus estimate of $94.74 million. On average, analysts expect Ascendis Pharma A/S to post $-7 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Ascendis Pharma A/S Stock Down 1.8 %

Shares of ASND stock traded down $2.22 during trading hours on Friday, hitting $124.33. 459,304 shares of the company were exchanged, compared to its average volume of 443,282. The firm has a fifty day moving average of $132.54 and a 200 day moving average of $133.30. Ascendis Pharma A/S has a 1 year low of $86.54 and a 1 year high of $161.00. The firm has a market cap of $7.54 billion, a PE ratio of -13.59 and a beta of 0.66.

Wall Street Analysts Forecast Growth

ASND has been the topic of a number of recent research reports. Citigroup boosted their target price on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a "buy" rating in a research report on Tuesday, September 17th. TD Cowen lifted their target price on Ascendis Pharma A/S from $157.00 to $160.00 and gave the company a "buy" rating in a research note on Monday, October 21st. Cantor Fitzgerald reiterated an "overweight" rating and set a $170.00 price target on shares of Ascendis Pharma A/S in a research report on Monday. Evercore ISI upped their target price on Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an "outperform" rating in a research report on Tuesday, September 17th. Finally, Wells Fargo & Company lifted their price target on Ascendis Pharma A/S from $264.00 to $289.00 and gave the stock an "overweight" rating in a research note on Tuesday, September 17th. Two analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $195.92.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.